Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

AstraZeneca buys into Daiichi ADC

by Lisa M. Jarvis
April 5, 2019 | A version of this story appeared in Volume 97, Issue 14

 

AstraZeneca will pay Daiichi Sankyo $1.35 billion to jointly develop the antibody-drug conjugate trastuzumab deruxtecan. The ADC combines a HER2-targeting antibody with a topoisomerase I inhibitor, with the goal of delivering the powerful chemotherapy directly to cancer cells. The companies plan to file for regulatory approval of the drug, now in studies to treat people with HER2-expressing breast and gastric cancers, later this year. Daiichi, which will produce the drug, stands to rake in another $5.5 billion in sales and other milestone payments.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.